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Till Bisse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Samarbetet mellan människan och naturen har alltid varit väldigt sofistikerat. Från antikens 
greker som använde giftig sjölök, fylld av hjärtglykosider, som ett hjärtstimulerande medel, 
till örtgumman som tipsade forskaren William Withering om att den vackra blomman 
digitalis hjälper mot ödem; från äldre tiders svenskar som helt modigt drack 
liljekonvaljsnaps mot hjärtproblem och hela vägen fram till den moderna medicinen digoxin 
(som används mot paroxysmal supraventrikulär takykardi) – människor har alltid varit 
instinktiva farmakognoser! 
 
Elin Unnes, författare till boken “Herbariet – växter till mat, magi och medicin” 

  
ABSTRACT 
 
Graft-versus-host disease of both the acute (aGvHD) and chronic (cGvHD) variety remains a 
major cause of mortality and morbidity after allogeneic hematopoietic stem cell 
transplantation (HSCT). During the last 15 years, mesenchymal stromal cells (MSC) have 
been explored as a promising new treatment for aGvHD, but there are many questions to be 
answered in this young field.  
The aim of this thesis is to expand our understanding of MSC treatment and GvHD with a 
specific focus on safety, factors affecting the outcome of MSC therapy and the possibility of 
treating also cGvHD with MSC. 
In paper I we performed a long-term follow up study of the first patients treated with MSC, 
and reported on their outcome. We demonstrated a high frequency of infections and 
recommend the use of prophylactic drugs and close surveillance of patients during and 
following MSC treatment. Regarding factors affecting the outcome, we reported an 
association between low passage MSC and better clinical outcome, indicating that MSC lose 
some of their potency with extensive culturing. In paper II, we analysed autopsy reports and 
tissue samples from patients treated with MSC and could demonstrate that MSC do not 
appear to engraft in the patients. The risk of malignant transformation of donated MSC 
should therefore be very low.  
In paper III we demonstrated a correlation between vitamin D deficiency prior to HSCT and 
an increased incidence of cGvHD, indicating vitamin D deficiency as a possible risk factor 
for cGvHD.  
Paper IV reports on a clinical trial of MSC therapy in refractory cGvHD. Eleven patients 
were included; of whom nine received up to six repeated infusions of MSC and could be 
evaluated for response. Of these nine, six patients responded to MSC therapy with durable 
improvement in cGvHD symptoms and could significantly reduce systemic 
immunosuppression.  
To summarize, this thesis provides new data regarding the safety of MSC therapy and 
suggests that the use of MSC is relatively safe, provided that necessary precautions are taken 
regarding infectious complications. With this information at hand, we could move forward to 
expanding the use of MSC in conditions with less dire expectations than refractory aGvHD, 
such as cGvHD. The clinical study of MSC therapy in cGvHD is one of the largest reported 
worldwide and suggests that repeated infusions of MSC could be a valuable treatment option 
for these patients.  
 
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
I benmärgen finns de stamceller som bildar våra blodceller, såväl röda blodkroppar som de 
vita blodkroppar som utgör vårt immunsystem. Vid benmärgstransplantation byter man 
därför ut ett sjukt immunsystem, vid exempelvis leukemi, mot ett friskt från en donator. Men 
när inte immunsystemet matchar kroppens egna celler perfekt kan man få en 
avstötningsreaktion som kallas transplantat-kontra-värd reaktion, eller GvH av den engelska 
förkortningen. Denna kan komma snabbt efter transplantationen och ge en häftig, akut 
reaktion med blåsor i huden, diarré och leverpåverkan som kan vara dödlig trots behandling. 
Den kan också komma senare, i en kronisk form som kan visa sig upp till ett par år efter 
transplantationen och mer likna reumatiska sjukdomar med ledvärk, torra slemhinnor och 
hudutslag.  
I benmärgen finns också en annan typ av stamceller som bildar ben, fett och bindväv och 
skapar en anpassad livsmiljö för blodstamcellerna. Dessa så kallade mesenkymala celler 
interagerar även direkt med immunförsvarets celler och verkar ofta som en dämpande kraft 
för att lugna ner immunsystemet och motverka skada när immuncellerna är alltför aggressiva. 
Därför har man sedan början av 2000-talet provat att behandla akut GvH med donerade 
mesenkymala celler. De lämpar sig också väl för behandling, eftersom de kan mångfaldigas i 
cellodling och inte behöver matchas mellan givare och mottagare. Behandlingen har visat sig 
ha viss effekt, men väckte också en del oro för biverkningar som ökade infektioner eller att de 
donerade cellerna skulle bilda tumörer i kroppen. Mycket återstår också att förstå kring 
behandlingen, som vilka faktorer hos patienten, donatorn eller hanteringen av cellerna som 
kan påverka effekten.  
I den här avhandlingen studeras säkerheten hos behandling med mesenkymala celler, och 
vilka faktorer som kan påverka eller förutsäga effekten av behandlingen. Vi har också 
studerat effekten av D-vitaminbrist innan transplantationen, framför allt vad gäller 
uppkomsten av kronisk GvH. Slutligen har vi studerat effekten av behandling med 
mesenkymala celler vid kronisk GvH. 
I det första arbetet genomförde vi en återblickande långtidsuppföljning på alla patienter som 
fått mesenkymala celler på Karolinska Universitetssjukhuset Huddinge från 2002 (då den 
första behandlingen i världen gjordes) till 2007. Det var 31 patienter, varav de flesta (23) 
hade fått mesenkymala celler som behandling för akut GvH. Övriga 8 patienter hade fått dem 
som behandling för blödning i urinblåsan, vilket också är en allvarlig komplikation efter 
benmärgstransplantation.  
Det visade sig att risken att dö av infektioner var hög även lång tid efter tillfrisknande från 
den akuta sjukdomen. Vi försökte spegla behandlingen i provrörsexperiment där patientens 
immunceller fick reagera på donatorns mesenkymala celler. Resultatet av experimenten 
kunde dock inte förutsäga huruvida en patient skulle svara på behandlingen i verkligheten. 
Däremot verkar celler som genomgått färre odlingscykler ha bättre effekt än de som odlats 
  
längre. Patienterna som fått celler som odlats i högst två cykler svarade bättre på 
behandlingen och överlevde i större utsträckning än övriga.   
I det andra arbetet gick vi igenom obduktioner som gjorts på 18 patienter som avlidit efter 
att ha genomgått behandling med mesenkymala celler. Hos ingen av dem fanns tecken till 
tumörer eller vävnad som bildats av de donerade cellerna. Vävnadsprover från 15 av 
patienterna analyserades närmare med DNA-teknik, vilket visade mycket små mängder av 
kvarvarande donerade celler i patientens kropp. Ju kortare tid som gått från att cellerna givits 
tills att vävnadsprovet togs, desto större var chansen att några celler skulle kunna påträffas. 
Slutsatsen blev att de donerade mesenkymala cellerna endast verkar överleva en kort tid i 
kroppen och att behandlingen därmed verkar säker ur det hänseendet. 
I det tredje arbetet fokuserade vi på D-vitaminbrist, och om det kan påverka det nybildade 
immunförsvaret efter benmärgstransplantation på ett negativt sätt. D-vitamin har en funktion i 
regleringen av immunsvaret, och brist på D-vitamin misstänks kunna öka risken för 
autoimmuna sjukdomar som reumatoid artrit, MS och typ 1 diabetes. Vi kunde utnyttja 
blodprover som tagits innan transplantationen och sparats frysta för att i efterhand ta reda på 
vilka patienter som haft D-vitaminbrist före transplantationen, och sedan utifrån journalen 
läsa ut hur det gått för dem. Vi kunde då se att de patienter som haft låga D-vitaminnivåer 
före transplantationen hade en högre risk att utveckla kronisk GvH. Utifrån denna studie kan 
vi dock inte dra några slutsatser om huruvida det är D-vitaminbristen som orsakar den ökade 
risken och om det i så fall skulle löna sig att ge extra D-vitamin inför transplantationen, utan 
man skulle behöva gå vidare och undersöka det med hjälp av en kontrollgrupp.  
Det fjärde arbetet är en behandlingsstudie där vi testat att ge upprepade behandlingar av 
mesenkymala stamceller för att behandla patienter med svår kronisk GvH. Elva patienter har 
påbörjat behandlingen, två fick avbryta i förtid och vi kan därför inte utvärdera om deras 
behandling haft någon effekt. Av de nio som fullföljt minst ett halvårs behandling har sex 
stycken svarat med lindring av symtomen och kunnat minska ned på övrig immunhämmande 
behandling. De har behandlats i ungefär nio månader och förbättringen verkar hålla i även 
efter att vi avslutat behandlingen, flera patienter är nu mer än ett år efter sista behandlingen 
med mesenkymala celler och är fortfarande klart förbättrade. Två patienter har kunnat 
upphöra med alla immunhämmande läkemedel.  
Slutsatserna i avhandlingen är att behandling med mesenkymala celler verkar vara relativt 
säkert, men att vi bör ge förebyggande behandling mot svampinfektioner och ha noga uppsikt 
på andra infektioner även lång tid efter att patienterna läkt ut sin GvH, något som nu är rutin 
på kliniken. Mesenkymala celler verkar också lovande som behandling av kronisk GvH, men 
vi behöver gå vidare med fler studier för att förstå varför vissa patienter inte svarar på 
behandlingen och om vi kan hitta sätt att göra behandlingen effektivare för fler patienter. 
Trots 15 års kliniska studier har hittills ingen genomfört en övertygande, kontrollerad studie 
som visar effekt av mesenkymala celler. Det behöver inte betyda att det inte finns någon 
effekt, men området är svårt att studera. Kliniska studier på GvH har flera inneboende 
  
svårigheter, det är ett sällsynt tillstånd med svårt sjuka patienter där man ibland måste fatta 
snabba beslut om behandling. Behandlingen med mesenkymala celler har även den sina 
svårigheter, med variationer mellan olika donatorer, oklarheter i vilken hantering av cellerna 
som är bäst och avsaknaden av test som visar vilka celler som har bäst effekt. Sammantaget 
tror jag att vi har en större chans att kunna visa effekt av cellbehandling vid andra sjukdomar 
än GvH, till exempel inflammatoriska tarmsjukdomar eller reumatologiska sjukdomar, och 
det bedrivs också mycket studier på dessa sjukdomar. Vi borde samarbeta mer mellan 
forskningsgrupper och lära oss av deras resultat. Ett exempel är behovet av ett test som 
förutsäger cellernas effekt, om sådana studier kunde bedrivas parallellt med stora kliniska 
studier i flera sjukdomsgrupper kunde resultaten sedan användas för att förbättra 
cellprodukten och därmed resultaten. 
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1 INTRODUCTION 
 
Imagine a garden. There are flowers, bushes and trees, but beneath the plants, vital for the 
growth, is the soil. If the soil is thin and dry, the plants will not be able to prosper. In a rich 
soil, full of nutrients, the plants will thrive. This is a picture of the haematopoietic niche of 
the bone marrow, where the haematopoietic stem cells (HSC) thrive in a supporting 
environment.  
The milieu in the bone marrow is the stroma (from Greek, meaning ”layer, bed, bed 
covering”); vasculature, bone, fat and connective tissue. This microenvironment is crucial for 
the regulation of HSC differentiation and self-renewal, as mutations affecting the stromal 
cells of the bone marrow can seriously hamper haematopoiesis (1).  Mesenchymal stromal 
cells (MSC) in the bone marrow, the source of bone, cartilage, fat and connective tissue cells, 
also have direct effects on many of the differentiated immune cells, orchestrating the 
inflammatory reaction.  
Following HSC transplantation, the HSCs enter a bone marrow that has been damaged by 
conditioning cytotherapy and radiation. The few new stem cells, about 5% of the stem cell 
mass of a healthy bone marrow, must expand to fill the niche and give rise to progenitor cells 
that can differentiate into blood and immune cells. This happens under the pressure of 
inflammatory signalling from damaged tissues. When the regulation of the developing 
immune system goes awry it reacts against the host tissue, creating graft-versus-host disease 
(GvHD).  
Here we question: If the bone marrow stromal cells can interact with the immune system and 
dampen immune responses, maybe infusion of donated MSC could be effective in treating 
GvHD? This has been tried during the last decade with some success. But infusion of third-
party cells with stem cell capacity raises safety issues, such as the risk of tumour formation.  
The aim of this thesis is to expand our understanding of GvHD and MSC treatment. It 
focuses on the safety and potential efficacy of the treatment for chronic GvHD, as well as 
factors that could predict or improve patient outcome. The study also explores the possible 
association between vitamin D deficiency and the development of chronic GvHD. 
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2 HEMATOPOIETIC STEM CELL TRANSPLANTATION 
 
2.1 HISTORY 
The first initiative to explore transplantation of HSCs came in the wake of the atomic bomb, 
when animal experiments demonstrated the possibility of rescuing mice exposed to lethal 
doses of radiation by transferring bone marrow from a healthy animal (2). The first human 
transplantation ensued shortly after (3), but the initial enthusiasm rapidly declined due to 
dismal results in the early years (4). With the discovery of the human leukocyte antigen 
(HLA)-system (5) and the possibility to choose a “suitable” donor, in combination with better 
understanding of the importance of pre-treatment of the patient, hematopoietic stem cell 
transplantation (HSCT) in patients with severe haematological malignancies grew 
exponentially during the 1970s (6). In 2013, the total number of performed transplantations 
worldwide reached 1 million, the majority of which were for haematological malignancies 
(7).  
In the early stages, all transplantations performed were allogeneic, transferring bone marrow 
from another (healthy) person to the patient. The development of autologous transplantation 
quickly followed (8). In this case the patient’s own hematopoietic cells are cryopreserved 
whilst the patient undergoes high dose radiation and/or chemotherapy. This treatment 
effectively targets the malignancy at the expense of bone marrow toxicity, which can then be 
rescued by re-infusion of the preserved hematopoietic cells. Autologous transplantation is 
safer with regards to immunological complications as the problem of immunological 
compatibility is avoided. However, there is a risk of contaminating the graft with malignant 
cells when the malignancy is present in the haematological compartment. In addition, a major 
advantage of allogeneic transplantation is the immunological clearance of malignant cells 
achieved by the graft-versus-tumour (GvT) effect, explored in chapter 2. Autologous 
transplantation will not be discussed further in this thesis and the abbreviation HSCT will be 
used referring to allogeneic transplantations herein.  
 
2.2 HLA TYPING 
HLAs are the human equivalents of major histocompatibility complex (MHC) molecules 
(reviewed in 5). MHC class I correspond to HLA-A, B and C and present peptides produced 
inside the cell, either endogenous or viral, for recognition by CD8+ cytotoxic T-cells. MHC 
class II correspond to HLA-DR, DP and DQ and are present on specialized antigen-
presenting cells, such as dendritic cells, where they present peptides from phagocytized 
foreign cells, such as bacteria, and are recognized by CD4+ T-helper cells.  
HLA antigens are coded for on chromosome 6. A person carries two HLA haplotypes, one 
inherited from the mother and one from the father, therefore the chance of a sibling carrying 
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the same two haplotypes, to be HLA-identical, is 25%. A donor with one identical HLA 
haplotype (for example in the case of a parent donating HSCs to a child, or vice versa) is 
called haploidentical. When searching for an unrelated donor, HLA-matching on at least 8 
HLA antigens (2 each for HLA-A, B, C and DR) is sought after. Typing in our institution is 
performed for 12 HLA antigens.  
This is an extremely simplified explanation of compatibility, complicated by the existence of 
minor histocompatibility antigens inherited outside of the HLA gene complex (9). This 
means that HLA-identical siblings are still not entirely immunologically compatible like 
genetically identical (syngeneic) twins are. 
 
2.3 TRANSPLANTATION PROCEDURE 
The transplantation procedure involves: 
i) A conditioning regimen with chemotherapy and/or radiation that weakens the 
patient’s own immune system to pave the road for the transplanted cells. This also 
serves to eradicate as many as possible of remaining malignant cells. 
ii) Infusion of donated HSCs 
iii) GvHD prophylaxis 
iv) Supportive care including prophylaxis for infectious diseases 
The conditioning regimen varies with the underlying disease and the clinical status of the 
patient. High dose myeloablative regimens, frequently involving whole-body irradiation, 
were initially ubiquitous and are effective in eradicating both the host immune system and 
malignant cells. This results in low rates of graft rejection and relapse, but at a cost of high 
cellular toxicity (10). In the late 1990s, reduced-intensity conditioning (RIC) regimens were 
introduced (11), making it possible to transplant older patients with more co-morbidities.  
HSCs can be obtained directly from the bone marrow by iliac aspiration, from apheresis of 
peripheral blood after mobilization with granulocyte colony stimulating factor (G-CSF) or 
from umbilical cord blood. Peripheral blood stem cells (PBSC) are the most commonly used, 
with the advantage of faster engraftment, reducing the risk of neutropenic infections, but with 
increased risk of cGvHD compared to bone marrow (12). Umbilical cord blood expands the 
available donor pool due to less HLA restriction, but is associated with slower engraftment 
and increased risk of opportunistic infections (reviewed in 13), therefore making it an option 
only when another suitable donor cannot be found.  
Regardless of stem cell source, the cell graft is made up of a mixture of HSCs, progenitor 
cells and mature mononuclear cells, though the proportions vary somewhat. The cell graft is 
infused into a central venous catheter and the HSCs home from the circulation to the bone 
marrow (14).  
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GvHD prophylaxis is necessary in all allogeneic settings, but as it counteracts the beneficial 
GvT effect the regimen is adjusted both by the risk of GvHD and the risk of relapse. The 
routine at Karolinska University Hospital generally follows the recommendations of the 
European Group for Blood and Marrow Transplantation (EBMT) and the European 
Leukaemia Network (ELN) (15). The basis of prophylaxis is a calcineurin inhibitor directed 
against interleukin (IL)-2 mediated T-cell activation. This treatment strategy is continued for 
a minimum of 3 months after HSCT, longer when the donor was unrelated, and up to a year 
in non-malignant disease. It is combined with a short course of methotrexate early post-
transplant. In vivo T-cell depletion with anti-thymocyte globulin (ATG) is added in unrelated 
donor transplants or non-malignant disease. 
 
2.4 IMMUNE RECONSTITUTION AND INFECTIONS 
During the initial neutropenic phase, patients are deeply immunosuppressed and mucosal 
barriers damaged due to conditioning therapies, leading to a high risk of bacterial infections 
(16) as well as invasive candida infections (17). Antibiotic and antifungal prophylaxis during 
the neutropenic phase is routine at our centre.  
Circulating neutrophil and monocyte levels return to normal within a few weeks post-
transplant, though neutrophil functions, such as chemotaxis and phagocytosis, can be 
impaired especially in the setting of GvHD (18). Macrophages are more resistant to 
chemotherapy and initially tissue macrophages of host origin can be found, but they are 
gradually exchanged with donor macrophages (19). Natural killer (NK) cells are restored to 
normal levels within the first month post-transplant (20). With a relatively restored innate 
immune system and intact mucosal barriers, the risk of bacterial infections drops significantly 
after the first month. 
In contrast, the T- and B-cells of the adaptive immune system take longer to recover. An 
early expansion of mature T-cells in the graft gives rise to a limited repertoire during the first 
year post-HSCT, followed by thymus-dependent development of naïve T-cells (21). This 
process can be delayed or inhibited by factors affecting the thymus function, most notably 
older age and GvHD (22). B-cells are first undetectable in peripheral blood, starting to 
increase during the second month post-HSCT, but maintaining an immature phenotype with 
limited immunoglobulin (Ig)G production for up to two years post-transplant (23).  
This prolonged immunodeficiency, augmented by GvHD and GvHD treatments, leaves the 
patients at high risk of viral infections. Re-activation of latent viruses, including 
cytomegalovirus (CMV) (24), Epstein-Barr virus (EBV) (25) and varicella zoster (VZV) (26) 
are major threats and routine monitoring of CMV, as well as EBV in risk patients, is 
performed. Valaciklovir-prophylaxis to prevent shingles is administered for the first year 
post-HSCT. Toxoplasma can also re-activate, causing severe infections, and prophylaxis is 
needed if the patient is sero-positive (27). Acute respiratory viral infections are common both 
during and after the neutropenic phase and can lead to life threatening lower respiratory tract 
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infections (28). Pneumocystis carinii-associated pneumonia is rare due to routine 
prophylaxis, but associated with significant mortality and morbidity (29). Invasive fungal 
infections are a risk primarily in the setting of GvHD, where prophylaxis is recommended 
(30). A summary of immune reconstitution, infection risk and recommended prophylaxis is 
presented in Figure 1. 
 
 
Figure 1. Schematic overview of the time-line of immune deficiencies, infections and recommended 
prophylaxis after HSCT.   
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3 GRAFT-VERSUS-HOST DISEASE AND GRAFT-
VERSUS-TUMOUR EFFECT 
 
3.1 ACUTE GRAFT-VERSUS-HOST DISEASE 
The main effector cell population in aGvHD are cytotoxic T-cells from the graft. Depletion of 
mature T-cells from the graft significantly reduces the risk of aGvHD (31). The 
immunological response of these T-cells is, in essence, completely normal as the cells react to 
the foreign environment, a process further triggered by danger signals from tissues damaged 
by conditioning therapy or infections (32). Damage to the gut mucosa causes translocation of 
intestinal bacteria over the mucosal barrier (33), and bacterial toxins, such as 
lipopolysaccharide (LPS), further increase the “cytokine storm” that propagates aGvHD (34).  
 
The major organs affected by aGvHD are the skin, gut and liver. Most commonly, patients 
first present with a rash and at initiation of therapy approximately 81% of patients have skin 
involvement, 54% gut dysfunction and 50% liver dysfunction (35). The diagnosis is mainly 
clinical, but histopathological evaluation is sometimes needed to distinguish from other 
disorders such as CMV colitis (36). The liver is rarely biopsied due to the risk of bleeding 
complications. The severity of aGvHD is usually graded according to the revised Glucksberg 
criteria (37) (Table 1), where each organ is staged 0-4 and then an overall grade of I-IV is 
derived based on the combination of organ stages. The overall grade correlates to survival, 
with approximately 25% long-term survivors in patients with grade III and less than 5% 
survivors for grade IV (38).  
As aGvHD usually develops during the first 100 days after HSCT (35), patients are generally 
still on calcineurin-inhibitor based prophylaxis. First-line treatment for aGvHD is 
methylprednisolone (15), but durable, complete remissions are only achieved in about 35% of 
patients treated with steroids alone (39). If the patient does not respond to prednisolone, 
defined as no response after 7 days or clear progression after 5 days (15), there is no standard 
second-line treatment option and the general recommendation is that patients should, if 
possible, be treated in clinical trials (15).    
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Table 1. Revised Seattle Glucksberg scoring system for aGvHD 
Stage Skin Liver  
(bilirubin) 
GI  
(diarrhoea volume) 
0 No rash <2 mg/dL < 500 mL/day  
1 Rash <25% of BSA 2-3 mg/dL 500-999 mL/day or 
persistent nausea* 
2 Rash 25-50% of BSA 3.1-6 mg/dL 1000-1500 mL/day 
3 Rash >50% of BSA 6.1-15 mg/dL >1500 mL/day 
4 Generalized erythema 
and bullae 
>15 mg/dL Severe abdominal pain 
or ileus 
Grade Skin Liver GI 
I Stage 1-2 0 0 
II Stage 3 or: Stage 1 or: Stage 1 
III - Stage 2-3 or: Stage 2-4 
IV Stage 4 or: Stage 4 - 
Adapted from Przepiorka et al, Bone Marrow Transplant 1995. * Persistent nausea with histological 
evidence of aGvHD in the stomach or duodenum.  
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3.2 CHRONIC GRAFT-VERSUS-HOST DISEASE 
 
3.2.1 Diagnosis and staging 
Traditionally, all GvHD appearing >100 days after HSCT was termed chronic (cGvHD). 
However, this fails to reflect the different pathophysiological mechanisms, as well as distinct 
clinical features, in the acute and chronic forms. aGvHD can be seen more than 100 days 
after HSCT, especially in reduced intensity transplants, late tapering of immunosuppressive 
drugs or following donor lymphocyte infusions. To clear this distinction and ameliorate 
studies in the field, a National Institute of Health (NIH) conference was held in 2004 to 
establish consensus criteria for diagnosis and staging of cGvHD (40) and response criteria for 
conducting clinical studies in cGvHD (41). This was later followed by a second conference in 
2014, with some revision of the initial criteria (42, 43).  
Under this definition, GvHD is divided into aGvHD or cGvHD based on the clinical 
characteristics. Patients demonstrating symptoms associated with aGvHD (erythema, 
vomiting, diarrhoea, cholestatic liver disease) without meeting the criteria of cGvHD are 
diagnosed as aGvHD, regardless of time from HSCT. Patients with classical cGvHD 
symptoms (sclerosis of skin and mucosa, bronchiolitis obliterans, fasciitis, joint contractures) 
are diagnosed as cGvHD, with a further sub-division of classic chronic (in the absence of 
aGvHD features) or overlap syndrome (if also at least one symptom associated with aGvHD 
is present). See Figure 2.  
 
Figure 2. Schematic of differential diagnosis of acute and chronic GvHD. HSCT: haematopoietic 
stem cell transplantation DLI: donor lymphocyte infusion. Adapted from Jagasia et al, BBMT 2015.  
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cGvHD features 
No current aGvHD 
symptoms:  
Classic cGvHD 
Coincidal aGvHD 
symtpoms:  
Overlap syndrome 
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After diagnosis of cGvHD, the stage is defined as mild, moderate or severe according to the 
degree of organ involvement and severity of symptoms (40,42). 
3.2.2 Treatment 
Corticosteroids, with or without the addition of calcineurin inhibitors, constitute the basis of 
cGvHD treatment (15). Unfortunately, only approximately half of the patients achieve long-
term remission on this first-line treatment (44) and as in aGvHD, there is no established 
second-line treatment (15, 45).  Prolonged treatment with corticosteroids carries significant 
risks including type II diabetes, osteoporosis, muscle atrophy, hypertension, psychological 
disturbances and infections.  
The most well documented second-line treatment is extracorporeal photopheresis (ECP), with 
reported response rates of approximately 60% (46). It is the only second-line treatment in 
cGvHD that has been evaluated in a randomized controlled study (48), but this study failed to 
reach its primary endpoint. A 2010 survey of EBMT centres reported that the most 
commonly used second-line therapies were ECP (53%), mycophenolate mofetil (36%), 
rituximab (12%), calcineurin inhibitors (12%), mammalian target of rapamycin (mTOR) 
inhibitors (9%), corticosteroids (8%) and tyrosine kinase inhibitors (6%) (48). More recent 
additions include low-dose IL-2 (49) and bortezomib (50). 
 
3.3 PATHOPHYSIOLOGY OF CHRONIC GVHD 
The pathophysiology of cGvHD is complex and not fully understood. It involves both the 
adaptive and the innate immune system and it is possible that different pathophysiological 
mechanisms dominate the picture in different clinical manifestations of the disease. Some of 
the main pathophysiological mechanisms discussed below are summarised in a schematic 
overview in Figure 3. 
3.3.1 T-cells 
Alloreactive T-cells from the graft as well as decreased thymic function are involved in the 
initiation of cGvHD. The classical paradigm stated that cGvHD, as opposed to acute, was a 
T-helper (Th)2-driven disease (51). This has been challenged by recent studies showing an 
active role of Th1, as well as Th17 cells, in at least sclerotic skin cGvHD (52), with IL-17A 
produced by CD8+ cytotoxic T-cells as well as CD4+ Th17 cells seemingly central to the 
development of sclerodermatous disease (53). CD4+ lymphopenia with a skewing towards 
less regulatory T cells (Tregs), in relation to conventional T-cells, is a common feature of 
cGvHD (54); with clinical studies aiming at expanding Tregs with low-dose IL-2 therapy 
demonstrating encouraging early results (55).  
Another T-cell subset that has recently come into focus in cGvHD research is T follicular 
helper cells (TFH). TFH cells interact with B-cells in germinal centres of lymphatic tissue 
and promote B-cell activation and Ig production (56). Aberrant TFH activation could impair 
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the positive selection of B-cell clones and has been suggested as a pathophysiological 
mechanism in several autoimmune diseases, where increased levels of circulating activated 
TFH cells have been found to correlate with disease activity (reviewed in 57). Irregular TFH 
functionality with increased frequencies of activated TFH cells have also been reported in 
cGvHD (58). 
3.3.2 B-cells 
B-cell dysregulation seems to be at the heart of cGvHD development (reviewed in 59), with 
slow B-cell regeneration (60) and high levels of circulating B-cell activating factor (BAFF) 
detected (61). This elevated BAFF/B-cell ratio impairs the normal negative selection of 
alloreactive B-cells (62). However, the mechanisms behind this dysregulation and role of B-
cells in the pathophysiology of cGvHD remain largely unknown and areas of intense 
investigation.  
Auto-antibody production is a common feature in cGvHD (63, 64). Anti-platelet derived 
growth factor receptor (PDGFR)-antibodies have been suggested to exert a direct effect in 
promoting tissue fibrosis (65), but the functional relevance of these antibodies is unclear (63, 
66). Rather, the role of B-cells as antigen-presenting cells and their production of pro- or anti-
inflammatory cytokines have been the primary focus to date (reviewed in 67).  
Allen et al. reported that B-cells derived from cGvHD patients are highly activated and 
resistant to apoptosis (68). Specific subsets, including transitional CD21- B-cells are 
increased in cGvHD (69, 70), whilst CD27+ memory B-cells (69) and regulatory B-cells (71) 
are reduced. It is important to note however, that these data can be somewhat contradictory, 
with other reports indicating higher levels of CD27+ cells (72). CD21- B-cells have also been 
demonstrated to be anergic (73) and thus might not be relevant to the disease 
pathophysiology.  
3.3.3 Fibrosis and the innate immune system 
Central to the cGvHD pathology is the development of fibrosis, similar to several other 
chronic inflammatory diseases such as systemic sclerosis, primary biliary cirrhosis or 
idiopathic pulmonary fibrosis. Fibrosis is characterised by differentiation of myofibroblasts 
that lay down excessive amounts of extracellular matrix (reviewed in 74). The mechanisms 
driving and regulating myofibroblast differentiation are poorly understood, but macrophages 
appear to play a complex, orchestrating role with both pro- and anti-fibrotic properties (75, 
76). Macrophages display several phenotypes, depending on the surrounding environment, 
and different phenotypes exhibit different features in the development of fibrosis (reviewed in 
77). Transforming growth factor (TGF) β, secreted by macrophages, is a major driving force 
in the development of fibrosis (75, 78). But macrophages are also instrumental in the 
resolution of fibrosis (79) and can under certain circumstances inhibit inflammation-driven 
fibrosis (76). 
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Figure 3. Schematic overview of some pathophysiological mechanisms in cGvHD.   
Tissue damage, from aGvHD, pathogens or other trauma, initiates danger signals that trigger 
activation of the innate immune system. Macrophages and T follicular helper (TFH) cells drive B-cell 
dysregulation. Activated Th17 cells and cytotoxic T-cells react towards allo-antigens. Il-17A from T-
cells and innate lymphoid cells (ILC) as well as TGF β from macrophages induce myofibroblast 
differentiation and fibrosis development.  
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Innate lymphoid cells (ILC) are cells of lymphoid origin but lacking antigen-specific 
receptors and therefore part of the innate immune system (80). They are rare in the 
circulation, but enriched in tissues near epithelial borders where they interact closely with 
tissue-resident macrophages and are involved in chronic inflammation and fibrosis (reviewed 
in 81). ILC are divided into three subtypes ILC1, ILC2 and ILC3, mirroring the T helper 
subtypes Th1, Th2 and Th17 (80). The ILC2 subtype is implicated in pulmonary fibrosis (82, 
83), whilst ILC3 is an important source of IL-17A, which as discussed above appears to be 
central to the development of sclerodermatous cGvHD (53). In psoriasis patients, increased 
proportions of ILC3 have been isolated from active skin lesions (84). 
Monocytes, macrophages and dendritic cells are also major producers of BAFF (85, 86) and 
dysregulation of BAFF production in monocytes has been demonstrated in patients with 
Sjögren’s syndrome (87). This might be a further driving mechanism in the B cell pathology 
discussed above. B-cells and BAFF can also have direct effects on fibroblasts, promoting 
fibrosis in systemic sclerosis (88). 
 
3.4 RISK FACTORS FOR GVHD 
Many known risk factors for GvHD can be classified as either relating to immune mismatch 
between the donor and the patient or to tissue damage and impaired restorative capacity in the 
patient, which can be understood in the context of disease pathophysiology as described 
above.  
Belonging to the first category are HLA-mismatch between donor and patient (89), allo-
immunization of the donor by transfusion or pregnancy (90) and female donor to male 
recipient (90,91). The composition of the donor cell graft also impacts the outcome, with a 
higher risk of GvHD in PBSC transplants compared to bone marrow grafts (92). In umbilical 
cord blood cell transplantations instead, some degree of HLA-mismatch can be allowed 
without increasing the risk of GvHD (93), though the HLA-matching remains important (94). 
This can, to some extent, be explained by the proportions of mature, alloreactive T-cells in 
the grafts, as a higher total nucleated cell dose is associated with higher risk of cGvHD (95). 
In the second category we find older patient age (90) and higher intensity conditioning 
(mainly total body irradiation) (96). For cGvHD, a major risk factor is previous aGvHD (97), 
which falls within this category both through direct damage to target tissues such as skin and 
through destruction of the thymus, leading to impaired T-cell reconstitution (98).  
Many studies reporting on risk factors predate the NIH diagnostic criteria for cGvHD and 
thus the distinction between acute and chronic forms is not clear. A large study from 2011, 
comprising nearly 3000 patients, aimed to compare the effect of various risk factors on 
aGvHD and NIH-defined cGvHD (99). PBSC and older patient age were found to be only 
associated with cGvHD, whilst total body irradiation was only linked to aGvHD. In addition, 
many risk factors were found to be common to both forms of GvHD but the statistical 
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measures of cGvHD risk were not affected by adjusting for prior aGvHD, indicating 
independent mechanisms.  
 
3.5 VITAMIN D 
A newly suggested risk factor for cGvHD is vitamin D deficiency (100). Cholecalciferol, or 
vitamin D, is a fat-soluble vitamin obtained partly from ingestion of certain foods, but mainly 
by the transformation of 7-dehydrocholesterol in the skin when exposed to sufficient levels of 
sunlight. As many HSCT patients have been hospitalized for long periods of time, in addition 
to suffering from mucosal damage and limited nutrition, it is not surprising that the incidence 
of vitamin D deficiency is high within this population (101).  
Cholecalciferol needs to be activated by the enzyme 1-α-hydroxylase. This was previously 
believed to take place only in the kidneys, but 1-α-hydroxylase has later been found to be 
active in many parts of the body, including dendritic cells and macrophages (102). Active 
vitamin D may play a vital role in regulating the immune system, including inhibition of 
alloreactive T-cells (103). Several observational studies have reported on associations 
between vitamin D deficiency and autoimmune diseases, including multiple sclerosis (104) 
and type 1 diabetes (105). Deficiency of vitamin D has also been implicated as a risk factor 
for rejection of solid organ transplants (106).  
In 2012, Glotbecker et al. reported on 53 adult patients demonstrating a significant 
association between low vitamin D levels prior to HSCT and increased incidence of cGvHD 
(107). This finding could however not be confirmed by a later study comprising 123 
paediatric patients (108), but the latter study reported a very low overall incidence of cGvHD 
which could explain the lack of correlation. More studies are needed to explore the question 
of whether vitamin D deficiency is a risk factor for the development of cGvHD.  
 
3.6 GRAFT-VERSUS-TUMOUR EFFECT 
The other side of the GvHD coin is the immunological anti-tumour effect known as graft-
versus-tumour (GvT) or graft-versus-leukaemia (GvL). This was suggested in early animal 
experiments (109) and was later confirmed as clinically relevant in human HSCT (110,111). 
Patients with aGvHD or cGvHD displayed lower relapse rates than unaffected patients.  
However, Horowitz et al. (111) further indicated that the GvT effect, to some extent, was 
mediated by allogeneic T-cells independent of the GvHD. Patients receiving T-cell depleted 
grafts, with or without GvHD, displayed higher relapse rates than in non-T-cell depleted 
transplants without GvHD. Furthermore, patients receiving a graft from an identical twin had 
more than twice the relapse risk of other patients without GvHD.  
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Later studies have confirmed an association between cGvHD and lower relapse rates (112), 
whilst the impact of aGvHD seems to be dependent also upon the conditioning regimen (113, 
114). A reduced intensity conditioning does not confer a significant anti-tumour effect in 
itself but must rely more heavily on the GvT than in the myeloablative setting. Regardless, it 
appears to be possible to achieve lesser GvHD rates with T-cell depleted grafts (115) or in 
vivo T-cell depletion using ATG (116) without affecting the leukaemia-free survival, at least 
in unrelated transplants. 
On a biological level it is evident that T-cells driving the GvT and GvH response might 
respond to the same mechanisms but have different antigen specificities. In GvT the T-cells 
react towards hematopoietic cells and possibly malignancy-specific antigens, whilst in GvH 
epithelial and other tissue-antigens are in focus. Different techniques for isolating 
malignancy-specific T-cells for adoptive transfer (117) or vaccination against malignancy-
associated epitopes (118) are currently being explored.  
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4 MESENCHYMAL STROMAL CELLS 
 
4.1 BACKGROUND 
In 1968, Friedenstein et al. published a characterisation of cells found in the bone marrow 
that could form ectopic bone tissue (119). These cells, originally named mesenchymal stem 
cells, constitute about 0.001 to 0.01% of the bone marrow mononuclear cells and can 
differentiate into adipose tissue, bone and cartilage (120). Cells with the same phenotypic 
properties have later been derived from other tissues, notably umbilical cord blood (121), 
adipose tissue (122) and skin (123).  
 
4.2 DEFINITION 
Today we appreciate that mesenchymal stem cells represents a heterogeneous composition, 
with no single, definitive marker identified to date. In order to better define this cell 
population, criteria regarding phenotype and function were imposed by The International 
Society for Cellular Therapy in 2006 (124). We therefore define this cell population by their 
adherence to plastic, spindle-like morphology and their tri-lineage plasticity; the ability to 
differentiate into bone, cartilage and fat. In addition, the cells have to be at least 95% positive 
for surface markers CD73, CD90 and CD105, whilst negative for haematopoietic markers 
CD34, CD45, CD11b, CD14, CD19 and CD79α, as well as HLA-DR (124).  
The same association proposed that the name multipotent mesenchymal stromal cells (MSC) 
was to be preferred over mesenchymal stem cells (125), to account for the fact that the 
definition includes many cell populations, several of which do not fulfil the self-renewal and 
multi-lineage potential of true stem cells. Through this thesis MSC will refer to mesenchymal 
stromal cells as defined above. 
As these cells are so rare in vivo, knowledge of their functions comes from studies using 
MSC that have been expanded in vitro, a process that most certainly affects their 
functionality. What immunological functions endogenous MSC actually exert in vivo still 
remains to be established. In this chapter, I will focus on the immunomodulatory properties 
exerted by expanded bone marrow MSC in vitro and in animal models.   
 
4.3 LICENSING AND POLARIZATION 
The interactions between MSC and the immune system are highly complex and dependent on 
environmental triggers (reviewed in 126). In the absence of pro-inflammatory stimuli, MSC 
support the survival of T-cells (127), as well as B-cells (128), and rescue T-cells from 
activation-induced cell death (127). When stimulated with interferon- γ (IFN-γ) MSC display 
potent anti-inflammatory properties (129), a process known as ‘licensing’ (126). This 
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licensing appears dependent on the concentration and duration of IFN-γ stimulation (130) and 
is also affected by several other cytokines such as tumour necrosis factor- α (TNF-α) (131). 
However, in the presence of bacterial LPS, MSC can react through activation of toll-like 
receptor (TLR) 4 with a production of pro-inflammatory cytokines such as IL-6 and IL-8 and 
stimulate T-cell activation (132). This discovery has led to the postulation that MSC can be 
polarized into two distinct phenotypes, the pro-inflammatory MSC1 and the anti-
inflammatory MSC2 (132).  
 
4.4 MECHANISMS OF IMMUNOMODULATION 
There are several, possibly mutually redundant, mechanisms for MSC to exert an 
immunosuppressive effect. When co-cultured with activated T-cells in mixed lymphocyte 
reactions (MLR), they suppress T-cell proliferation (133). This suppression could be achieved 
in transwell (133) and several soluble factors have been identified as effectors, including 
TGF-β (133), prostaglandin E2 (PGE2) (134) and indoleamine 2,3-dioxygenase (IDO) (135). 
However, more effective T-cell suppression could be achieved when cell contact was allowed 
(133). In addition to the numerous immunomodulatory soluble factors MSC secrete, they also 
produce chemoattractants (131), promoting lymphocyte migration and adhesion molecules 
(136), thereby allowing them to tightly bind lymphocytes. This potentially allows the soluble 
factors to work more efficiently, as well as providing an opportunity for membrane-bound 
factors, such as programmed death ligand 1 and 2 (PDL 1/2), to interact with specific 
lymphocyte receptors, PD-1 in this case (137).  
Besides directly suppressing cytotoxic T-cells, licensed MSC can induce CD4+ T-cells, 
including Th17 cells (138), into immunosuppressive regulatory T-cells, Tregs (139). MSC-
induced Treg induction is dependent on monocytes being present in the co-culture and 
skewing of these monocytes by MSC into anti-inflammatory M2 macrophages (140). Tregs 
and M2 macrophages are both potent anti-inflammatory mediators. In a mouse sepsis model, 
injected MSC accumulated in the lungs together with monocytes and macrophages. These 
macrophages were induced to produce large amounts of IL-10, which then mediated the 
protective effect against sepsis-related organ failure observed in the MSC-treated mice (141). 
These findings indicate the ability of MSC to both directly immunosuppress as well as 
indirectly modulating anti-inflammatory immune cells to coordinate the suppressive effects. 
In addition to their ability to immunomodulate through soluble factor secretion, MSCs are 
reported to modulate their environment through the production of micro-RNAs (miRNA) 
(142). These short, non-coding, single-stranded RNA molecules regulate the expression of 
target genes by binding to target sequences on mRNA. miRNAs can be transported from one 
cell to another in exosomes or microvesicles (143). The potential of MSC derived miRNAs 
have been demonstrated in a mouse model of hypoxic injury, where effects were ameliorated 
by transferring of MSC exosomes (144). miRNA-containing exosomes from human MSCs 
have also been reported to modulate macrophage activation (145) 
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Figure 4. Immunomodulatory mechanisms of MSC. Direct inhibitory effects on cytotoxic T-cells 
and Th17-cells via soluble factors, including IDO, PGE2 and TGF-β, and membrane-bound PDL-1. 
Indirect effects via reprogramming of monocytes and M1 macrophages into anti-inflammatory M2 
macrophages, and naïve T-cells and Th17-cells into Tregs. 
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4.5 MSC AND FIBROSIS 
In vivo, circulating or tissue-resident cells of mesenchymal lineage have been shown to 
differentiate into pro-fibrotic myofibroblasts (rev in 74). TGF-β, one of the main soluble 
factors secreted by MSC (133), is also a major inducer of myofibroblast differentiation and 
extracellular matrix production (146). Intravenous administration of MSC on the other hand 
has repeatedly been demonstrated to inhibit or ameliorate fibrosis in animal models (147-
150). 
This apparent paradox can to some extent be explained by the anti-inflammatory effects of 
MSC discussed above, as chronic inflammation is a major driving mechanism in the 
development of fibrosis. MSC and monocyte/macrophage interactions are probably a central 
feature of the inhibition of fibrosis as this usually is accompanied by less infiltration of 
macrophages (148, 150), and depletion of macrophages early in the inflammatory process is 
associated with less fibrosis development in tissue damage models (151). 
Another factor is the multi-functionality of TGF-β. TGF-β is secreted as an inactive pro-
peptide complex that after secretion can be bound to extracellular matrix components 
(reviewed in 152). This makes the concentration of free, active TGF-β dependent on several 
factors separate from the production. There are also three isoforms of TGF-β, where TGF-β1 
and 2 have the most prominent fibrotic properties while TGF-β3 has been suggested to be 
anti-fibrotic (153). A mouse model of wound healing indicated that locally injected MSC 
reduced fibrosis through shifting the ratio between TGF-β1 and TGF-β3 (154). 
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5 MSC THERAPY 
 
5.1 BASIC PRINCIPLES 
MSC have several properties that make them interesting for cell-based therapies. They 
express low levels of HLA class I and have been described as immune privileged, in that they 
do not elicit an immune response when transplanted across HLA barriers (155). Though this 
concept has been challenged (156), it remains true that MSC from unmatched, third-party 
donors can be transplanted without immunological reactions (157). MSC can be expanded in 
vitro (158) and cryopreserved (159), which allows for prepared doses of third-party MSC to 
be stored for future use. 
MSC have been investigated for cell therapy in several areas, including regenerative medicine 
(160), to support haematological recovery after HSCT (161) and as an immunosuppressive 
treatment for auto- or allo-immune reactions. Different modes of administration have also 
been investigated, including systemic infusion, local injection (162) and seeding on scaffolds 
to be implanted (163). In this chapter I will focus on systemic use of MSC as an 
immunosuppressive treatment.  
 
5.2 MSC PRODUCTS 
MSC for clinical use can be obtained from various tissues, most commonly bone marrow, 
adipose tissue (164) or perinatal tissues such as umbilical cord or foetal tissues (165). In 
experimental models, other tissues such as skin (166) and synovial membranes (167) are also 
being explored. The origin of the cells most likely greatly affects their immunomodulatory 
properties (168). 
Isolation of MSC from aspirated bone marrow relies on the plastic adherence of the MSC 
population, with some protocols plating whole unprocessed bone marrow for expansion 
(169). More commonly, the mononuclear fraction is first separated using density-gradient 
separation. The mononuclear cells, a mixture of haematopoietic stem and progenitor cells, 
lymphoid cells, monocytes, endothelial progenitor cells and MSC are then plated in flasks, 
where the MSCs adhere to the plastic and alter their morphology to a characteristic, spindle-
like shape. The medium needs to contain growth factors to allow for cellular proliferation and 
this was initially achieved by adding foetal calf serum (FCS). FCS is problematic in several 
ways, as it displays great batch-to-batch variation and carries a risk of unknown infectious 
agents. In later years, FCS has often been replaced by human serum or platelet-rich plasma.  
There is evidence that different protocols for isolation and expansion of MSC can greatly 
affect the properties of the cells (170-172). Add to this variability the fact that MSC from 
different donors can differ in secretory and immunomodulatory capabilities (173) and we 
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realize that there is currently no such thing as a uniform MSC product to be compared over 
different studies.  
 
5.3 ACUTE GVHD 
The first case of MSC treatment reported was in a 9-year-old child with severe aGvHD, 
reported by Le Blanc et al. (174). This initial patient was followed in 2008 by a multicentre 
report on 55 patients with steroid-refractory aGvHD (175), showing complete responses in 
55% and partial response in 16%, with no immediate side-effects to MSC administration.  
These encouraging results spurred several further studies, including an industry-sponsored 
randomized, placebo-controlled phase III trial that was presented as an abstract at the 2010 
American Society for Blood and Marrow Transplantation Tandem Meeting (176), but to date 
has not been published in full. The results of the phase III trial were discouraging, failing to 
meet the primary endpoint of increased durable complete responses for MSC compared to 
placebo. However, there are many reasons to be careful in interpreting this single trial as 
evidence that MSC are ineffective in treating aGvHD (177). A subgroup analysis 
demonstrated that patients with gut and/or liver involvement responded significantly better 
with MSC than placebo, though the overall effect was diminished by the patients with only 
skin involvement, where no difference in response was seen. It is also noteworthy to state that 
the MSC product used (Prochymal®) was highly expanded, up to 10 000 doses produced 
from few donors, whilst cells used in academic trials usually only produce 5-10 doses per 
donor. Our data indicate that extensive passaging could have a negative effect on MSC 
clinical efficiency (paper I). 
Recent reviews of the literature (178, 179) concluded that there is support for an effect of 
MSC on aGvHD, but stresses the need for a randomized phase III-study. There are currently 
13 active studies registered on clinicaltrials.gov with MSC therapy for the indication aGvHD, 
of which 7 are recruiting patients, as well as a European multicentre randomized, double-
blinded phase III-study led by the HOVON group (Table 2).  
Commercial MSC products have been approved in Japan for treatment of aGvHD and in 
Canada and New Zealand for steroid-refractory aGvHD in children. The response rate in 
children is usually reported to be higher than that observed in adults (180, 181), though there 
is no randomized study on a paediatric population.  
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Table 2: Studies registered on clinicaltrials.gov on MSC treatment of aGvHD 
Phase Control group Status* Sponsor  NCT identifier§ 
I/II No Completed Andalusian Inititative for Advanced 
Therapies 
NCT01222039 
II No Recruiting Nanfang Hospital of Southern Medical 
University 
NCT01765634 
I/II No Completed Grupo Espanol de transplantes 
hematopoyeticos y terapia celular 
NCT01956903 
III Yes (1) Completed Osiris Theraputics NCT00366145 
II No Recruiting University Hospital of Liege NCT00603330 
I/II No Not yet 
recruiting 
Andalusian Inititative for Advanced 
Therapies 
NCT02687646 
II Yes (3) Recruiting Royal Perth Hospital NCT01589549 
I/II No Recruiting National Heart, Lung and Blood Institute NCT02379442 
II/III Yes (3) Recruiting Nanfang Hospital of Southern Medical 
University 
NCT02241018 
I/II No Recruiting A.O. Ospedale Papa Giovanni XXIII NCT02032446 
I/II No Completed UMC Utrecht NCT00827398 
I/II No Ongoing, not 
recruiting 
Affiliated Hospital to Academy of 
Military Medical Sciences 
NCT01754454 
III No Recruiting Mesoblast International Sàrl NCT02336230 
Search 2016-04-04 on “graft-versus-host OR gvhd / mesenchymal OR MSC”. Studies that are 
terminated or of unknown status are excluded, as are studies on cGvHD, of MSC as GvHD 
prophylaxis and local administration of MSC. * Study status as indicated on clinicaltrials.gov.  
§ Unique study identification number on clinicaltrials.gov. Control groups: 1 = randomized, placebo-
controlled, double-blind. 2= randomized, placebo-controlled, single-blind (patient). 3= randomized, 
open label, placebo or alternate treatment. 
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5.4 CHRONIC GVHD 
Compared to aGvHD, data on MSC treatment in cGvHD is sparse. The only studies including 
more than 10 patients come from Sun Yat-Sen University, Guangzhou, China, that have 
published several reports on MSC treatment on up to 38 patients and reporting response rates 
between 74% and 87% (182-185). However, it is not clear from the publications to what 
extent the patients are overlapping between the studies, so it is impossible to know the total 
number of patients treated. Common between the publications was that repeated infusions of 
MSC were administered (median 2-3) and that the responses were observed late (median time 
to best response 233 days in (183), between 3 and 6 months in (184)). 
Besides this group, there are only four published reports of MSC treatment in cGvHD. First, 
Ringdén et al. (186) included one cGvHD patient in their initial report on MSC treatment in 
GvHD, with a transient response to a single MSC infusion. In 2010, Zhou et al. (187) 
reported successful treatment of four patients with sclerodermatous cGvHD with repeated 
infusions (1 per week, total 4-8 infusions) of MSC. This was followed by mixed results in a 
study by Pérez-Simon et al. (188), reporting 8 patients with refractory cGvHD receiving 1-3 
doses of MSC with 4 patients responding (of which 2 were transient responses). Finally 
Hermann et al. (189) treated 7 cGvHD patients, with a median of 8 infusions of MSC, 
achieving 4 responses.  
 
5.5 OTHER INFLAMMATORY DISEASES 
Following the positive reports in aGvHD, MSC therapy has been applied to a variety of other 
inflammatory diseases. A large number of phase I/II studies have been published in 
inflammatory bowel disease (190) and multiple sclerosis (191), with a smaller but substantial 
number in inflammatory arthritis (192) and systemic autoimmune diseases as systemic lupus 
erythematosus, systemic sclerosis and Sjögrens syndrome (reviewed in 193). To date, several 
randomized, placebo-controlled studies have been registered in ClinicalTrials.gov (see table 
3), but no results have been published so far. 
Drawing on the regenerative potential of transplanted MSCs, as well as immunomodulatory 
properties, MSC have also been explored to ameliorate damage caused by ischemia and 
reperfusion injury (194). This includes ischemic heart disease where a randomized, double-
blinded placebo-controlled study has been published (195) with encouraging results, but 
underpowered to demonstrate efficacy. Uncontrolled studies have also shown some 
improvement in liver function in end-stage liver disease (196) and preservation of β-cell 
function in type 1 diabetes (197). 
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Table 3: Studies, with control groups, registered on clinicaltrials.gov on MSC treatment of 
inflammatory diseases 
Indication Phase Control 
group# 
Status* Sponsor  NCT identifier§ 
Crohn’s disease 
II/III 3 Not yet recruiting Nanfang Hospital of Southern 
Medical University,  
Sun Yat-sen University 
NCT02532738 
III 1 Active, not 
recruiting 
Mesoblast International Sárl NCT00482092 
III 1 Active, not 
recruiting 
Mesoblast International Sárl NCT01233960 
Ulcerative colitis I/II 2 Recruiting Affiliated Hospital to 
Academy of Military Medical 
Sciences 
NCT02442037 
Rheumatoid 
arthritis 
II/III 3 Completed Royan Institute NCT01873625 
II 1 Recruiting Mesoblast International Sárl NCT01851070 
I/II 2 Completed TiGenix S.A.U NCT01663116 
Systemic lupus 
erythematosus 
II 1 Not yet recruiting Medical University of South 
Carolina 
NCT02633163 
Type I diabetes 
mellitus 
II 1 Recruiting Uppsala University NCT02057211 
II 1 Completed Mesoblast International Sárl NCT00690066 
Multiple sclerosis I/II 1 Completed Andalusian Inititative for 
Advanced Therapies 
NCT01056471 
Neuromyelitis 
optica  
II 3 Recruiting Tianjin Medical University  
General Hospital 
NCT02249676 
Search 2016-04-04 on “autoimmune OR crohns OR inflammatory bowel disease OR ulcerative colitis 
OR systemic sclerosis OR arthritis OR SLE OR scleroderma OR multiple sclerosis | mesenchymal OR 
msc ”. # Only studies with a randomized control group are included. Studies that are terminated or of 
unknown status are excluded, as are studies using local administration of MSC. * Study status as 
indicated on clinicaltrials.gov. § Unique study identification number on clinicaltrials.gov. Control 
groups: 1 = randomized, placebo-controlled, double-blind. 2= randomized, placebo-controlled, single-
blind (patient). 3= randomized, open label, placebo or alternate treatment. 
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5.6 SAFETY OF MSC TREATMENT 
With a new therapy there are naturally questions regarding safety. MSC were quickly shown 
not to induce transfusion reactions, acute toxicity or clinically significant pulmonary 
embolisms (186) in immunocompromised patients. This has also later been confirmed in a 
meta-analysis including immunocompetent patients (157). However, there remained two 
main concerns. Firstly the risks associated with engraftment of the transplanted cells giving 
rise to ectopic tissue or malignant tumours in the recipient (198). Secondly, that the 
immunosuppressive effect might increase the sensitivity to opportunistic infections or 
recurrence of the malignant disease in the case of HSCT patients.  
Malignant transformation of murine MSC in culture has been widely reported (199), but 
conflicting reports were published regarding human cells (200, 201). This dispute was settled 
when the reports on malignant transformation could be shown to be misidentifications of 
contaminating cancer cell lines in the lab (202, 203). Human MSC thus seem a safer option in 
this regard than embryonic stem cells or induced pluripotent stem cells (198, 204). 
In systemic or local infections, MSC seem to have the capacity to act as a double-edged 
sword with both positive and negative effects reported. Their activation can be modulated by 
binding of TLRs (205) and by direct interaction with various bacteria (206), which allows the 
adaptation of the response in an infected environment. MSC can increase the phagocytic 
capacity of monocyte/macrophages (207), as well as neutrophils (208), whilst reducing the 
inflammation-induced organ damage. In vitro, MSC even exhibit direct anti-microbial effects 
mediated through LL-37 (209) and IDO (210). This suggests MSC therapy could be 
beneficial even in severe infections such as sepsis (211). 
Re-activation of viral infections such as CMV, EBV and adenovirus is a major risk in HSCT, 
especially in the setting of aGvHD. There has been conflicting evidence on whether MSC 
would impair the virus-specific immune response. Karlsson et al. reported that MSC did not 
inhibit proliferation of CMV- or EBV-specific T-cells in vitro and that CMV-specific cells 
could be obtained from the peripheral blood of two patients after MSC treatment for aGvHD 
(212). In contrast, Malcherek et al. demonstrated strong inhibition of CMV- and influenza-
specific T-cells by MSC in culture (213). MSC can also be directly infected by CMV (214) 
and this infection could markedly hamper the immunomodulatory capacities of the MSC 
(215). In follow-up studies of patient cohorts, MSC treatment has not been associated with 
higher incidence or mortality in CMV or EBV infections, but with a higher mortality in 
adenovirus infections (216, 217). 
Some studies report an increased incidence of invasive fungal infections (218) or pneumonia-
associated death (a large proportion of which was due to fungal pneumonia) (219) in patients 
treated with MSC. In treatment studies lacking control groups there are difficulties separating 
the increased risk of infectious complications due to the underlying disease from that of 
MSC, but in a randomized study on MSC as GvHD prophylaxis there was still a slightly 
higher risk of infections in the MSC-treated patients, despite them having a lower incidence 
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of aGvHD than the controls (220). This study by Ning et al. (220) also reported a markedly 
higher incidence of relapse in the patients with haematological malignancies. Though this 
relapse rate might explain some of the infections, it is in itself alarming. This phenomenon 
has not been confirmed in any other studies on co-transplantation of MSC in HSCT 
(reviewed in 221).  
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6 AIMS 
 
The principal aim of this thesis is to expand our understanding of GvHD and MSC treatment. 
Within this aim, focus has been placed on answering the following questions: 
 
1. Safety of MSC treatment. The early patient cohort at Karolinska University Hospital 
was the first to undergo MSC treatment. Follow-up studies of the treated patients 
were performed to evaluate the safety of systemic MSC treatment and long term 
complications with regards to infections, relapse, ectopic tissue formation and 
secondary malignancies. 
 
2. Prediction of response. Why do some patients respond to MSC treatment whilst 
others do not? Is this dependent on the individual patient, the physiology of disease, 
the MSC product or a combination of these factors? 
 
3. Vitamin D deficiency. Is there an association in patients undergoing HSCT between 
vitamin D deficiency and the risk of developing cGvHD or other related 
complications? 
 
4. MSC treatment of cGvHD. Could systemic treatment with MSCs be a potentially 
safe and effective treatment of refractory cGvHD? 
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7 PATIENTS AND METHODS 
 
7.1 PATIENTS 
Paper I details a long-term follow-up of MSC treated patients. All patients treated with MSC 
for aGvHD (n = 23) and haemorrhagic cystitis (HC) (n = 8) between 2002 and 2007 at the 
Karolinska University Hospital were included. The cohort consisted of 24 males and 7 
females, with a median age of 53 years (range 1-67). Data was collected from the patient 
medical records and complications were recorded from the date of first MSC infusion until 
the last date of data collection in November 2009. 
In paper II the engraftment of infused MSC and the risk of ectopic tissue formation or 
malignant transformation was evaluated. Nineteen patients treated with MSCs at Karolinska 
University Hospital between 2002 and 2010 were included, partially overlapping with the 
cohort of paper I. The patients received MSCs for GvHD (n = 11), HC (n = 5), 
haemophagocytic lymphohistiocytosis (n = 2) and for the promotion of engraftment (n = 1). 
Eighteen of the patients were evaluated by autopsy and samples were analysed for MSC 
donor DNA within multiple organs from 15 patients. 
Paper III is a retrospective cohort analysis including 166 consecutive patients (> 12 years of 
age) undergoing HSCT between 2005 and 2011 at Karolinska University Hospital. In the 
analysis of cGvHD incidence, patients with graft failure (n=13) or with a survival after HSCT 
of less than 100 days (n=14) were excluded. All data was taken from patient medical records, 
and all complications, except infections, were recorded from the date of HSCT to the last date 
of data collection, in April 2014. Infectious complications were only recorded for the 1st year 
following HSCT. 
Paper IV forms a clinical study for the treatment of cGvHD with systemic, allogeneic MSC 
therapy. Patients diagnosed with cGvHD of grade moderate to severe, refractory to or not 
tolerating 3 months standard treatment of calcineurin inhibitor plus steroids were included. 
Eleven patients with severe cGvHD were enrolled, 6 female and 5 male, with a median age of 
50 (range 20-61). Patients were clinically evaluated up to 1 year after last infusion for 
response.  
All studies were conducted in accordance with the Helsinki convention and approved by the 
regional ethical committee in Stockholm. Written informed consent was obtained, for paper I 
and II at time of MSC treatment, for paper III at HSCT and for paper IV at study enrolment.  
 
7.2 DEFINITIONS 
In paper I and III, data concerning complications were obtained from medical records.  
CMV disease was defined according to Ljungman et al. (222). Invasive fungal disease was 
defined according to De Pauw (223). Only probable and proven invasive fungal infections 
were considered in paper III, whilst local fungal infections are reported separately in paper I. 
Diagnosis of pneumonia required either a combination of new pulmonary infiltrates on chest 
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X-ray or CT scan with symptoms of respiratory infection such as cough, dyspnoea or fever, 
excluding idiopathic pulmonary syndrome or autopsy-verified infectious pneumonia. 
Bacteraemia was defined as the first positive blood culture during a 10 day time period. 
Repeated positive blood cultures >10 days after the first were considered new episodes. In 
paper I, bacterial and viral infections were classified as severe (causing hospitalization or 
organ damage) or mild (other).  
Rejection (paper I) or graft failure (paper III) was defined as lack of engraftment, engraftment 
with recipient cells or later developing full (>95%) recipient chimerism in the absence of 
relapse of the underlying disease. In paper I, transplant-related mortality was defined as death 
occurring in the absence of relapse. In paper III, disease-free survival was defined as survival 
with no evidence of relapse or progression for malignant disease. Overall survival was 
defined as the time from HSCT to death, regardless of cause.  
In paper III and IV, cGvHD was diagnosed and scored according to the NIH consensus 
criteria (40), with both classic cGvHD and overlap syndrome included, but not late onset 
aGvHD. Only cGvHD of moderate and severe grade were considered in the analysis in paper 
III. Response evaluation in paper IV followed the NIH consensus recommendations (43). 
 
7.3 MSC THERAPY 
MSCs from the bone marrow of healthy donors were harvested and expanded following a 
procedure developed by the European Group for Blood and Marrow Transplantation 
Developmental Committee and accredited by the Swedish National Board of Health and 
Welfare under Swedish law 2008:286 (Cell- och vävnadslagen) (approvals number 952/2009, 
6.3.3-8874/2011, 6.1.3-9791/2013 and 6.1.3-16411/2015). Donors provided written, 
informed consent before the procedure. 
Bone marrow was harvested under sterile conditions by aspiration from the iliac crest. Bone 
marrow mononuclear cells were seeded in cell culture flasks in culture medium supplemented 
with 10% foetal calf serum. The cells were detached with 0.05% Trypsin-EDTA when they 
were 90% confluent and replated in new flasks for 1-4 passages. After harvest, the cells were 
cryopreserved. Release criteria were based on the absence of visible clumps, spindle shape 
morphology, the absence of contamination by pathogens (bacteria and mycoplasma) and 
viability >95%. The MSCs expressed CD73, CD90, CD105 and HLA-ABC and were 
negative for CD14, CD31, CD45 and HLA-DR as assessed by flow cytometry. 
In paper I and II, the majority of patients received a single infusion of MSC at a dose of 1-
2x106 cells/kg bodyweight. Ten patients in paper I and 9 in paper II received repeated MSC 
infusions, because of recurring or worsening symptoms after an initial good response, or 
because of lack of response. In paper IV, a dose of 2x106 MSC/ kg was infused at 4-6 week 
intervals. A minimum of 6 doses was given; in the case of response to treatment after 6 doses 
an additional 1-3 doses were infused. 
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7.4 LABORATORY ASSAYS 
Two different T-cell suppression assays were used in paper I, both using Ficoll-separated 
peripheral blood mononuclear cells (PBMCs) from the patients and MSCs from the same 
donor given as treatment. The PBMCs were activated using either irradiated PBMCs from 
five unrelated donors or phytohemagglutinin. Irradiated MSCs were then added in a 
proportion of 10% MSC to patient PBMCs and the proliferation of patient PBMCs was 
estimated by tritiated thymidine incorporation. Lower proliferation compared to controls 
(without MSC) was interpreted as T-cell suppression.  
Polymerase chain reaction (PCR) was used in paper II to identify cells of MSC donor 
origin in tissue samples. It relies on finding a DNA-sequence that is present in the MSC 
donor but not in the patient or the HSCT donor. In the first three patients a nested PCR 
method was used based on differences in the HLA type. This method is not quantitative and 
can thus only determine whether or not MSC donor DNA was present in the tissue. In the 
remaining analysed patients, quantitative real-time (qRT) PCR was used, based on single 
nucleotide polymorphisms (SNPs).  The sensitivity in both assays was the same, between 
1/105 and 1/106 as assessed by serial dilutions. 
 
7.5 STATISTICS 
Papers I, II and IV are mainly descriptive in nature and the statistical methods used are the 
Mann-Whitney U-test, Student’s T-test or Fisher’s exact test depending on the data. 
Probability of survival was estimated using the Kaplan-Meier method and compared using 
the log-rank test (Mantel-Cox).  
In paper III, cumulative incidence functions (CIF) were used to estimate GvHD, considering 
death and relapse to be competing events. Probabilities of DFS and OS were calculated using 
Kaplan-Meier estimates. Univariate analyses were performed using Gray’s test for CIF and 
the log-rank test for DFS and OS. Associations of patient and graft characteristics with 
outcomes were evaluated in multivariate analysis, using Cox proportional hazards model for 
dichotomous variables, or negative binomial regression analysis for outcomes with repeated 
events or continuous variables. For two-sample comparisons, the Wilcoxon rank-sum test or 
Fisher’s exact test was used.  
GraphPad Prism® 6, IBM SPSS version 21 and R 3.0.1 software were used. 
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8 RESULTS AND DISCUSSION 
 
8.1 SAFETY OF MSC TREATMENT (PAPER I, II, IV) 
The first reported case of MSC treatment in human was in 2002, at Karolinska University 
Hospital (174). Between 2002 and 2007 30 further patients were treated with MSC at our 
institution for either aGvHD or HC. At this time not much was known about possible 
negative long-term effects of the MSC treatment. As we had the largest treated patient cohort 
in the world, as well as the longest experience, we wanted to summarize the outcome in a 
follow-up report in paper I. In paper II, the focus was the risk of ectopic tissue formation or 
malignant transformation of infused MSC.  
To be able to separate the effect of MSC treatment from that of other immunosuppressive 
treatments, and from the aGvHD itself, it would have been necessary to have a control group. 
For a control group to be appropriate it needs to be well matched, preferably by 
randomization, and both groups need to be sufficiently sized (powered) to allow for statistical 
analysis. As there was no suitable control group available, we chose to report the 
complications in the MSC-treated cohort descriptively in both absolute numbers and as a 
function of observation period (incidence per 1000 patient-days). 
8.1.1 Infections 
We could demonstrate a high incidence of infectious complications, even long after MSC 
treatment and resolution of aGvHD. Out of 13 patients who recovered from aGvHD 
following MSC treatment, 7 (54%) later died from infections. Furthermore, the HC patients, 
who did not receive as much immunosuppression as the aGvHD patients, also displayed a 
high rate of infections including invasive fungal infections (see table 4 reproduced from 
paper I). Other reports from our institution have later confirmed an association between 
MSC treatment and infections (218, 219), whilst a large meta-analysis concluded the opposite 
(157). In this meta-analysis mainly patients without concurrent immunosuppression were 
included, which might account for the discrepancy in results. It should be noted that no 
routine anti-fungal or anti-viral prophylaxis was given during the time period under study. 
We recommend prophylaxis as well as close surveillance of patients treated with MSC to 
reduce the risk of infections and this is now routine in our clinic.  
In paper IV, repeated infusions of MSC were administered over a time period of 6-12 
months, in 9 patients with severe cGvHD. All the patients received prophylaxis against 
Pneumocystis jirovecii and were followed regularly with PCR for CMV viremia. We 
recommended anti-fungal prophylaxis with posaconazol, but because of intolerable side 
effects some patients received fluconazol or no anti-fungal agent. All patients were monitored 
closely for infectious complications during the MSC treatment period and for 12 months after 
the last infusion. No invasive fungal infections or CMV reactivations were recorded during 
this time, and a total of five events of grade 3 infections occurred.  
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Table 4. Severe infectious complications recorded in paper I 
 MSC GvHD n = 23 MSC HC n = 8 
 Total Incidence 
/1,000 d 
Total Incidence 
/1,000 d 
Severe bacterial 
infection 
27 2.0 8 2.8 
Severe viral infection 5 0.4 3 1.0 
Severe fungal infection 10 0.7 3 1.0 
EBV-activation 7 0.5 1 0.3 
PTLD 2 0.1 0 0 
CMV MSC GvHD  n = 19 MSC HC n = 7 
Peak (log10) 
Mean ± 95% CI 
4.1 ± 0.22 3.2 ± 0.37 
CMV disease 
Total (%) 
6 (32%) 0 (0%) 
MSC: mesenchymal stromal cells, GvHD: graft-versus-host disease, HC: hemorrhagic cystitis, EBV: 
epstein-barr virus, CMV: cytomegalovirus. In the CMV columns, seronegative patients receiving a 
seronegative graft are excluded. Adapted from von Bahr et al., BBMT 2012. 
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8.1.2 Relapse 
With strong immunosuppression in patients with an underlying malignant disease, the risk of 
abrogating the GvT effect and causing a relapse is present. One early study of co-
transplantation of MSC at HSCT demonstrated a higher incidence of leukaemia relapse (220), 
although later studies have not been able to confirm this finding (reviewed in 221). 
In paper I, 2 out of 27 patients (7%) with haematological malignancy suffered relapse, one 
with myeloma and one with acute lymphocytic leukaemia (ALL). In paper IV, 2 out of 11 
patients had relapse, one with myeloma and one with chronic lymphocytic leukaemia (CLL). 
As cGvHD is associated with a stronger GvT effect than aGvHD (112) and the treatment as 
well as follow-up time was longer in paper IV, this incidence is worth noting for future 
studies on cGvHD. On the other hand, both myeloma and CLL are diseases known to have 
relatively high relapse rates following HSCT and the patient cohort is too small for any 
conclusive results. In other published reports on MSC trials in cGvHD, a total of 6 cases of 
relapse have been reported among a total of 40 patients (185, 187-189). It should be noted 
though that it is not entirely evident from these publications how long a follow-up this 
reflects and thus no event rate can be calculated. The incidence of relapse in MSC treated 
patients needs to be followed up in future studies, preferably with larger cohorts and 
appropriate controls.  
8.1.3 Engraftment 
MSCs have a capability in vitro to differentiate into bone, adipose tissue and cartilage (120), 
and at least a portion of the culture-expanded MSCs infused intravenously for 
immunomodulatory treatment can be assumed to retain this capacity. Engraftment and 
proliferation of infused cells could lead to the development of ectopic tissue in the patients 
and possibly also malignant transformation. To address this question, we investigated 
autopsies of 18 patients as well as tissue samples from 15 patients who had received MSC. 
This study was published in paper II. 
No ectopic tissue and no evidence of malignant transformation of MSC could be found on the 
18 autopsies. In 7 patients, low levels of MSC donor DNA could be detected in samples from 
one or more tissues. One patient was severely ill with septicaemia and massive 
gastrointestinal bleeding at the time of MSC infusion and later developed disseminated 
intravascular coagulopathy, before passing away 7 days after receiving MSC. In this patient 
extensive micro- and macro-embolization was found at autopsy as well as detectable MSC 
donor DNA in all sampled tissues. We believe that the disturbed haemostasis in this patient 
explains the wide distribution of MSC in the tissues and that under normal circumstances the 
engraftment of infused MSC is very low. The detection of MSC donor DNA was negatively 
correlated with time from infusion to sampling, indicating that remaining cells may be 
subsequently cleared by phagocytosis.  
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8.2 PREDICTION OF RESPONSE (PAPER I AND IV) 
We know that some patients seem to respond well to MSC treatment, whilst others do not 
(175). This could depend on MSC donor variability, other factors related to the MSC product, 
patient factors or a combination thereof, including the matching between MSC donor and 
patient. If we understood more about the factors determining the response, this could be 
extremely helpful in selecting the best MSC product as well as choosing the patients that will 
benefit from the treatment.  
8.2.1 MSC donor and product  
In paper I, different factors of the MSC donor and MSC product were correlated to clinical 
outcome, divided into response (complete or partial) or no response. Thirty-one patients 
received a total of 45 infusions, on the indication of aGvHD (n=23) or HC (n=8) and each 
infusion was analysed separately for short-term response. No correlation was found between 
MSC donor age or sex and clinical response. The dose of MSC, varying between 0.65 and 3.0 
x106 /kg bodyweight, was also not correlated to response.  
The number of expansion passages of the MSC did however seem to affect the outcome, 
indicating a possible negative effect of in vitro culturing on the MSC properties. Patients 
receiving early-passage MSC (harvested after one or two passages) displayed both better 
short-term response and overall survival than patients receiving MSC of higher passage (three 
or four). In later studies, we have demonstrated that MSC can trigger the instant blood 
mediated inflammatory reaction (IBMIR) at intravenous infusion and that this triggering is 
stronger with higher passage MSC (224). Triggering of IBMIR may cause the MSC to be 
lysed and cleared from the circulation to a higher degree, potentially explaining the better 
outcome using low passage cells. Cryopreservation of high passage MSC might aggravate 
this problem, as later indicated in a small cohort of patients (225). We now aim at delivering 
low passage MSC for treatment. However, in order to achieve sufficient numbers of cells for 
therapy, expansion for, on average, three passages is needed. We therefore continue to work 
on improving the handling of the cells to minimize the negative effects of passaging and 
cryopreservation.  
8.2.2 MSC donor – patient matching 
MSC can safely be transferred across HLA barriers (155) and the use of HLA-matched MSC 
was not associated with better clinical response (paper I) or engraftment (paper II). This 
does not exclude some possible positive effects of HLA-matching, as the patient cohorts are 
small, but it is safe to say that no major disadvantage could be demonstrated for patients 
receiving unmatched cells. As using unmatched cryopreserved cells allows for swift 
administration of the MSC treatment, this is of great importance especially in the setting of 
aGvHD, where disease progression is rapid.  
In paper I, we investigated whether the ability of MSCs from a particular donor to suppress 
the individual patients’ T-cells in an in vitro assay could be used to predict a clinical effect of 
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MSC from that donor in the same patient. This appeared not to be the case, as we found no 
correlation between in vitro suppressive activity and clinical response. Probably the in vitro 
assays used today are too blunt to capture the complex interactions in vivo between the MSC, 
different immune cells and other factors such as the coagulation and complement systems. 
8.2.3 Patient factors 
In paper I, we demonstrated a better clinical outcome in children than in adults with aGvHD. 
This has also been confirmed in later studies (180, 181) but is most likely not unique for 
MSC treatment. Patients with CMV disease before MSC treatment responded poorly, which 
is interesting as it has later been found that MSC can be infected with CMV and that this 
impairs their immunomodulatory properties (215). It could also be argued that the patient’s 
symptoms were more associated with the CMV disease than aGvHD and that the lack of 
response was caused by a delay in CMV-specific treatment. 
In paper IV we have investigated potential biomarkers for response in MSC treatment. We 
have considered both biomarkers that could distinguish responders from non-responders 
before initiation of treatment and early indicators of clinical response that would enable a 
faster evaluation than the current 6 months needed for clinical evaluation in cGvHD 
treatment.  
Among the screened possible biomarkers, C-X-C motif ligand (CXCL)-9 and CXCL10 
displayed a pattern that could be indicative of a predictive biomarker for response. Both act as 
chemokines to attract inflammatory cells to a site of tissue damage and are ligands for the 
receptor CXCR3, expressed on lymphocytes (226, 227). They are secreted from M1 
macrophages when stimulated with IFN-γ (228) and elevated plasma levels of both CXCL9 
and CXCL10 have previously been demonstrated to be associated with active cGvHD (229).  
In the evaluated patients, a reduction in plasma CXCL9 and CXCL10 corresponded to 
clinical response, whilst non-responders increased their plasma levels of both chemokines 
during the course of the treatment. What makes these chemokines especially promising as 
biomarkers is that in five of the seven analysed patients this distinction between responders 
and non-responders was evident after only one MSC infusion, long before clinical response 
could be evaluated. This did not reach statistical significance among the few patients 
included, but will be explored further in future patient cohorts.  
A problem common to all the MSC studies in this thesis is the small study cohort. Biomarker 
screening normally requires very large study cohorts, since corrections have to be made to 
account for type I errors due to multiple comparisons. However, when the aim is to identify 
biomarkers with a predictive value on the individual patient level, this small study cohort can 
be made into an advantage. Markers with a low predictive value will not be identified due to 
the low statistical power in the study and thus the identified candidate markers have a 
potential of being of real value. Whether these candidate markers do display a true correlation 
to response will need to be confirmed in further cohorts. 
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8.3 VITAMIN D DEFICIENCY (PAPER III) 
Vitamin D is important for the function of the immune system (reviewed in 230) and 
deficiency has been associated with an increased risk of both autoimmune disease (104, 105, 
231) and infection (232). In paper III, we performed a retrospective cohort study of 166 
patients who had undergone HSCT at Karolinska University Hospital and where serum 
samples from immediately before HSCT were stored in a bio bank. Vitamin D levels at the 
time of HSCT were retrospectively measured and correlated to clinical outcome.  
We demonstrated a higher risk of cGvHD in patients with low levels of vitamin D, with a 
threshold at 60 nmol/L and increasing incidence of cGvHD with decreasing vitamin D levels 
below this threshold (Figure 5). This confirmed previously published findings by 
Glotzbecker et al. (107) of an association between vitamin D deficiency and cGvHD. 
 
 
Figure 5. Correlation between vitamin D level and cGvHD incidence (paper III) 
Cumulative incidence of cGvHD, grade moderate-severe, in cohorts stratified by levels of 25-OH-D3, 
in nmol/L, prior to transplantation (N=139). Figure from von Bahr et al., BMT 2015. 
 
In addition, we could see indications of a lower overall survival in patients with vitamin D 
deficiency and in a multivariate model low vitamin D level at HSCT was a significant risk 
factor for death. Relapse incidence did not differ between vitamin D deficient and sufficient 
patients, despite the difference in cGvHD incidence.  
Infections during the first year following HSCT were recorded and correlated to vitamin D 
levels. After correction for multiple comparisons, CMV disease was positively correlated to 
low vitamin D levels in a multivariate model. Nine cases of CMV disease were recorded, 
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with all of the affected patients presenting with a vitamin D level before HSCT below the 
insufficiency level of 50 nmol/L.  
As this was a retrospective study, all findings are associations and even though care has been 
taken to account for confounding factors, it cannot be determined from these data whether 
vitamin D supplementation would affect the risk. The next step would be to perform a 
prospective study, including patients before HSCT and randomizing them to either vitamin D 
supplementation or placebo.  
 
8.4 MSC TREATMENT OF CHRONIC GVHD (PAPER IV) 
We performed a clinical trial of multiple infusions of MSC in patients with cGvHD, 
refractory to or not tolerating standard therapy of calcineurin inhibitors plus high dose 
steroids. The primary endpoint was clinical response according to NIH criteria (43) at the end 
of treatment. Patients should receive a minimum of six infusions to be evaluated for response.  
Eleven patients were included, one died of progressive cGvHD after only one infusion and 
one was taken off the study after three infusions because of a threatening CLL relapse. Of the 
nine evaluable patients, six were classified as responders and three as non-responders. The 
patients were followed in the study for 12 months after the last MSC infusion and clinically 
outside of the study for a median follow-up time of 38 months (12-55) from time of 
inclusion. The responders continued to show stable or declining symptoms for the entire 
follow-up period.  
This clinical improvement was matched by a reduction in immunosuppression, with two 
patients completely off systemic immunosuppression and two more free from steroids and 
tapering calcineurin inhibitors. Patient-reported quality of life also improved in the 
responders, whilst it decreased in the non-responders. Taken together, these results indicate 
that repeated infusions of MSC could lead to a significant and durable reduction in cGvHD 
symptoms in the majority of patients. 
The strengths of this study are the rigorous response evaluations, long follow-up time and the 
combination of physician-observed symptoms with patient-reported measures and biological 
analyses. Weaknesses are the small treatment group and the lack of a control group and thus 
no conclusions regarding efficacy of MSC treatment can be made. What we have learned 
from this study will however be of utmost importance to plan and set up a larger study. Based 
on the expected response rate we can make a power calculation to estimate the number of 
patients to include in treatment and control groups in order to be able to show a statistically 
significant effect.  
One problem in such trial design is estimating the chance of spontaneous improvement in the 
control group. The randomized study of ECP by Flowers et al. (47) reports improvement in 
28% of the control group at 12 weeks. Although this study was only focusing on skin GvHD, 
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this might be a relevant estimate. Using the response rate to MSC in our study (66%) and the 
response rate in the control group above, a basic power calculation aiming at 80% power 
indicates that we would need 25 patients in each group. This does not take into account the 
fact that some patients will likely be excluded during the study, in our study 2/11 (18%) and 
in the study by Flowers et al. 12%. If we account for a 15% drop out rate, we would need to 
include approximately 60 patients. Considering the scarcity of cGvHD patients, as further 
discussed in chapter 9, a study of this size would not be possible to conduct in a single site in 
Sweden. It would need a multi-centre approach, possibly including centres outside of Sweden 
as well.  
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9 CONCLUSION AND FUTURE DIRECTIONS 
 
The main conclusions drawn within this thesis are: 
1) That MSC treatment appears relatively safe, but is probably associated with an 
increased risk of infections, at least in previously immunosuppressed patients. 
Prophylactic treatments as well as close surveillance of patients is highly 
recommended.  
 
2) Vitamin D deficiency at time of HSCT is associated with an increased risk of cGvHD, 
CMV disease and a lower overall survival. Whether these risks can be diminished by 
vitamin D supplementation should be evaluated in prospective, randomized trials. 
 
3) Repeated infusions of MSC could lead to clinically significant, durable improvement 
in patients with severe refractory cGvHD.  
 
Despite 15 years of clinical research in MSC therapy, no randomized trial has been published 
demonstrating an immunomodulatory effect by systemic MSC treatment. Using clinical 
response as the outcome in studies is naturally the most relevant measure, but also logistically 
challenging and dependent on large, randomized patient cohorts. Focusing the clinical 
therapeutic studies in the area of GvHD further complicates the situation, as both aGvHD and 
cGvHD pose major difficulties for clinical studies.  
Both forms of GvHD are rare diseases, with a high estimate of incidence being approximately 
50 patients with refractory aGvHD and 25 with refractory cGvHD per year in Sweden (based 
on incidence of aGvHD and cGvHD in paper III, responsiveness to steroids as reported by 
McMillan et al. (39) and Koc et al. (44) and the number of patients undergoing HSCT in 
Sweden 2015 (personal communication, prof. Per Ljungman)). This could be compared to a 
prevalence of 20 000 patients with Crohn’s disease in Sweden (233).  
aGvHD can be difficult to diagnose adequately, at least without good availability of 
colonoscopy and histopathological examination and is a rapidly progressing disease with high 
mortality. This forces physicians to often begin treating aggressively without a definite 
diagnosis, which in many cases excludes patients from being entered into clinical trials. Even 
more difficult is the randomization of patients to placebo, which can be deemed unethical in 
acute situations.  
In cGvHD the urgency of diagnosis and initiation of treatment is not an issue, but instead the 
slow progress of the disease poses difficulties for the evaluation of response and also for the 
ethical questions regarding placebo. Response evaluation, finally, is a major obstacle in 
chronic but also to some extent in aGvHD, relying solely on clinical observations.  
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I believe there is a great need for well-executed randomized placebo-controlled studies on 
MSC in large patient cohorts, where an actual clinical effect could be demonstrated as proof-
of-principle. For reasons mentioned above, the conditions best suited for randomized trials of 
MSC treatment might not be found in the HSCT setting. Instead, I believe that diagnoses, 
such as Crohn’s disease or rheumatoid arthritis, with phase III trials on-going, might be the 
first where we could see efficacy data in placebo-controlled settings.  
This does not mean to say that we should not aim for placebo-controlled studies in GvHD, 
but we should learn from the experiences made in other diseases and collaborate if possible. 
In these studies, large effort could be dedicated to finding possible biomarkers for response 
and preferably laboratory studies on the MSCs used clinically could be performed using a 
variety of immunological assays to find surrogate markers for clinical response. If an 
immunological assay could be identified that correlated with clinical efficacy, this would be 
immensely useful to compare different MSC preparations in the purpose of improving the 
MSC product for clinical use.  
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